title: Evaluation of molecular genetic variation associated with deep venous thrombosis in lower limb fractures in traumatic patients.
abstract: BACKGROUND
  Genetic variation in multiple genes associated with hemostasis and thrombosis is well documented to impact the rates of future venous thromboembolism; in addition, trauma and orthopedic surgery in lower limb and immobilization are important factors in increasing the incidence of thrombosis. Gene mutation can be predisposing factor for thrombosis in traumatic patients under anti-coagulant agent prophylaxis. The aim of this study is to evaluate the different gene mutations in these patients.
  
  
  METHODS
  In this cross-sectional descriptive study, the sample consisted of 53 patients with deep venous thrombosis (DVT) and 32 traumatic patients without thrombosis as the control group. Two groups matched together according to sex, age, weight, and medications. DNA analysis for mutation of multivariate of genes in thrombosis was studied.
  
  
  RESULTS
  Regarding gene variations, there was statistically significant difference only in Prothrombin (Factor II, G20210A) between the patients with thrombosis and control group (P = 0.01). But, there was no difference between two groups considering other gene mutations. Mutation of Prothrombin gene (G20210A) was a predictive factor for thrombosis with odds ratio of 1.1 (CI 0.3-1.9).
  
  
  CONCLUSIONS
  According to the outcomes resulted from this study, genetic mutation in Prothrombin (Factor II [G20210A]) is one of the most important genetic variations involved in traumatic patients with DVT despite prophylaxis. Genetic mutation in Prothrombin appears to be predisposing factor for thrombosis associated with trauma.
authors.affiliation: Department of Orthopedic Surgery, Shohada Hospital, Tabriz, Iran. ali.tab.ms@gmail.com
authors.forename: Ali
authors.initials: A
authors.lastname: Tabrizi
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Bazavar
authors.forename: Asghar
authors.initials: A
authors.lastname: Elmi
authors.forename: Amir
authors.initials: A
authors.lastname: Vahedi
authors.forename: Nilsa
authors.initials: N
authors.lastname: Dourandish
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D017984:Enoxaparin / Q000627:therapeutic use; D005260:Female; D005264:Femoral Fractures / Q000150:complications / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011516:Prothrombin / Q000235:genetics*; D020246:Venous Thrombosis / Q000150:complications / Q000235:genetics* / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D011516:Prothrombin